DIORIO CHRIS PH.D.

SEC source: 0001209191-23-011915 · doc4.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 270,084

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on November 8, 2022.

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $123.50 to $124.45, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-009406 · doc4.xml · nonDerivative · entry 15

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,784

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on November 8, 2022.

F16 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $129.63 to $130.32, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-009406 · doc4.xml · nonDerivative · entry 14

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 273,084

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on November 8, 2022.

F15 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $128.49 to $129.47, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-009406 · doc4.xml · nonDerivative · entry 13

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 273,544

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on November 8, 2022.

F14 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $127.39 to $128.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-009406 · doc4.xml · nonDerivative · entry 12

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 274,046

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on November 8, 2022.

F13 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $126.28 to $127.10, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-009406 · doc4.xml · nonDerivative · entry 11

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 274,318

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on November 8, 2022.

F12 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $125.28 to $126.21, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-009406 · doc4.xml · nonDerivative · entry 10

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 275,242

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on November 8, 2022.

F11 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $124.28 to $125.26, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-009406 · doc4.xml · nonDerivative · entry 9

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 276,543

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on November 8, 2022.

F10 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $123.26 to $124.25, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-009406 · doc4.xml · nonDerivative · entry 8

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 277,784

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on November 8, 2022.

F9 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $128.06 to $128.11, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-009406 · doc4.xml · nonDerivative · entry 7

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 278,084

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on November 8, 2022.

F8 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $127.02 to $128.01, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-009406 · doc4.xml · nonDerivative · entry 6

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 279,984

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on November 8, 2022.

F7 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $125.97 to $126.96, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-009406 · doc4.xml · nonDerivative · entry 5

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,884

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on November 8, 2022.

F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $124.82 to $125.76, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-009406 · doc4.xml · nonDerivative · entry 4

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 281,984

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on November 8, 2022.

F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $123.58 to $124.34, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-009406 · doc4.xml · nonDerivative · entry 3

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 282,784

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on November 8, 2022.

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $122.60 to $122.66, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-009406 · doc4.xml · nonDerivative · entry 2

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 283,084

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on November 8, 2022.

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $121.20 to $122.06, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-009406 · doc4.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 284,484

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on November 8, 2022.

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $120.15 to $121.12, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-003538 · doc4.xml · nonDerivative · entry 2

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 287,784

F1 · kind: These shares were disposed of in non-discretionary transactions to cover the reporting person's tax withholding obligations in connection with the settlement of an award of restricted stock units.

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $120.38 to $121.0601, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-003538 · doc4.xml · derivative · entry 4

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,125

Underlying: Common Stock · 3,125 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Impinj common stock.

F4 · derivative.exercise_date: On April 12, 2021, the reporting person was granted 50,000 restricted stock units ("RSUs"), one fourth of which vested on April 12, 2022, with an additional one-sixteenth of such RSUs vesting every three months thereafter. One-sixteenth of these RSUs vested on January 12, 2023.

F4 · derivative.expiration_date: On April 12, 2021, the reporting person was granted 50,000 restricted stock units ("RSUs"), one fourth of which vested on April 12, 2022, with an additional one-sixteenth of such RSUs vesting every three months thereafter. One-sixteenth of these RSUs vested on January 12, 2023.

SEC source: 0001209191-23-003538 · doc4.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 289,010

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-001408 · doc4.xml · nonDerivative · entry 2

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 285,885

F1 · kind: These shares were disposed of in non-discretionary transactions to cover the reporting person's tax withholding obligations in connection with the settlement of an award of restricted stock units.

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $109.1101 to $110.05, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-001408 · doc4.xml · derivative · entry 4

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,813

Underlying: Common Stock · 3,906 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Impinj common stock.

F4 · derivative.exercise_date: On September 5, 2019, the reporting person was granted 62,500 restricted stock units ("RSUs"), one fourth of which vested on July 1, 2020, with an additional one-sixteenth of such RSUs vesting every three months thereafter. One-sixteenth of these RSUs vested on January 1, 2023.

F4 · derivative.expiration_date: On September 5, 2019, the reporting person was granted 62,500 restricted stock units ("RSUs"), one fourth of which vested on July 1, 2020, with an additional one-sixteenth of such RSUs vesting every three months thereafter. One-sixteenth of these RSUs vested on January 1, 2023.

SEC source: 0001209191-23-001408 · doc4.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 287,497

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-061961 · doc4.xml · nonDerivative · entry 2

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 283,591

F1 · kind: These shares were disposed of in non-discretionary transactions to cover the reporting person's tax withholding obligations in connection with the settlement of an award of restricted stock units.

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $109.6401 to $109.80, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-22-061961 · doc4.xml · derivative · entry 4

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,375

Underlying: Common Stock · 1,563 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Impinj common stock.

F4 · derivative.exercise_date: On June 15, 2020, the reporting person was granted 25,000 restricted stock units ("RSUs"), one fourth of which vested on June 15, 2021, with an additional one-sixteenth of such RSUs vesting every three months thereafter. One-sixteenth of these RSUs vested on December 15, 2022.

F4 · derivative.expiration_date: On June 15, 2020, the reporting person was granted 25,000 restricted stock units ("RSUs"), one fourth of which vested on June 15, 2021, with an additional one-sixteenth of such RSUs vesting every three months thereafter. One-sixteenth of these RSUs vested on December 15, 2022.

SEC source: 0001209191-22-061961 · doc4.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 284,203

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-055374 · doc4.xml · nonDerivative · entry 8

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 282,640

SEC source: 0001209191-22-055374 · doc4.xml · nonDerivative · entry 7

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 292,640

F7 · kind: Distribution of Common Stock held by DFT L.L.C. to its members for no consideration.

F8 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the reporting person.

SEC source: 0001209191-22-055374 · doc4.xml · nonDerivative · entry 6

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · by DFT L.L.C

Disclosed balance after: 572,494

F7 · kind: Distribution of Common Stock held by DFT L.L.C. to its members for no consideration.

SEC source: 0001209191-22-055374 · doc4.xml · nonDerivative · entry 5

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 284,307

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2022.

F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $114.97 to $115.95, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-22-055374 · doc4.xml · nonDerivative · entry 4

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 284,708

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2022.

F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $113.93 to $114.88, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-22-055374 · doc4.xml · nonDerivative · entry 3

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 286,251

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2022.

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $112.90 to $113.86, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-22-055374 · doc4.xml · nonDerivative · entry 2

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 288,207

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2022.

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $111.90 to $112.71, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-22-055374 · doc4.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 288,316

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2022.

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $110.83 to $111.76, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-22-054933 · doc4.xml · nonDerivative · entry 9

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 289,307

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2022.

F10 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $117.34 to $117.96, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-22-054933 · doc4.xml · nonDerivative · entry 8

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 291,043

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2022.

F9 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $116.32 to $117.29, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-22-054933 · doc4.xml · nonDerivative · entry 7

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 293,707

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2022.

F8 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $115.25 to $116.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-22-054933 · doc4.xml · nonDerivative · entry 6

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 294,307

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2022.

F7 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $112.79 to $113.26, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-22-054933 · doc4.xml · nonDerivative · entry 5

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 295,007

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2022.

F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $111.72 to $111.81, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-22-054933 · doc4.xml · nonDerivative · entry 4

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 295,318

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2022.

F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $110.60 to $111.54, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-22-054933 · doc4.xml · nonDerivative · entry 3

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 297,506

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2022.

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $109.58 to $110.51, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-22-054933 · doc4.xml · nonDerivative · entry 2

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 298,733

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2022.

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $108.55 to $109.31, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-22-054933 · doc4.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 299,307

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2022.

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $108.09 to $109.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-22-053668 · doc4.xml · nonDerivative · entry 3

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 304,307

F1 · kind: These shares were disposed of in non-discretionary transactions to cover the reporting person's tax withholding obligations in connection with the settlement of an award of restricted stock units.

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $79.62 to $80.2301, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-22-053668 · doc4.xml · nonDerivative · entry 2

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 304,590

F1 · kind: These shares were disposed of in non-discretionary transactions to cover the reporting person's tax withholding obligations in connection with the settlement of an award of restricted stock units.

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $78.56 to $79.52, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-22-053668 · doc4.xml · derivative · entry 5

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,250

Underlying: Common Stock · 3,125 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Impinj common stock.

F5 · derivative.exercise_date: On April 12, 2021, the reporting person was granted 50,000 restricted stock units ("RSUs"), one fourth of which vested on April 12, 2022, with an additional one-sixteenth of such RSUs vesting every three months thereafter. One-sixteenth of these RSUs vested on October 12, 2022.

F5 · derivative.expiration_date: On April 12, 2021, the reporting person was granted 50,000 restricted stock units ("RSUs"), one fourth of which vested on April 12, 2022, with an additional one-sixteenth of such RSUs vesting every three months thereafter. One-sixteenth of these RSUs vested on October 12, 2022.

SEC source: 0001209191-22-053668 · doc4.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 305,525

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-052732 · doc4.xml · nonDerivative · entry 3

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 302,400

SEC source: 0001209191-22-052732 · doc4.xml · nonDerivative · entry 2

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 302,460

F1 · kind: These shares were disposed of in non-discretionary transactions to cover the reporting person's tax withholding obligations in connection with the settlement of an award of restricted stock units.

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $84.2301 to $85.10, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-22-052732 · doc4.xml · derivative · entry 5

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,719

Underlying: Common Stock · 3,906 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Impinj common stock.

F4 · derivative.exercise_date: On September 5, 2019, the reporting person was granted 62,500 restricted stock units ("RSUs"), one fourth of which vested on July 1, 2020, with an additional one-sixteenth of such RSUs vesting every three months thereafter. One-sixteenth of these RSUs vested on October 1, 2022.

F4 · derivative.expiration_date: On September 5, 2019, the reporting person was granted 62,500 restricted stock units ("RSUs"), one fourth of which vested on July 1, 2020, with an additional one-sixteenth of such RSUs vesting every three months thereafter. One-sixteenth of these RSUs vested on October 1, 2022.

SEC source: 0001209191-22-052732 · doc4.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 303,852

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.